Drugs / BI 770371
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06806852 | May 2025 → Aug 2027 expected | head and neck squamous cell carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05327946 | May 2022 → Jul 2024 overdue | cancer | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05068102 | Mar 2022 → Sep 2026 expected | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06675929 | Jan 2025 → Jan 2026 | cirrhosis of liver, metabolic dysfunction-associated steatohepatitis | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 770371 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06806852 ↗ |
| Route | Intravenous | “infusion into a vein” NCT06675929 ↗ |